Invitation to presentation of Q-linea’s Interim report Q2-2020 on July 16, 2020
Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s interim report for the period January – June 2020 on Thursday, July 16, 2020 at 07:30 a.m. CET.
Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on July 16, 2020, at 13:00 – 14:00 p.m CET.
Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Q2 interim report followed by a Q&A-session.
To participate, please call any of the following phone numbers from:
Sweden: + 46 8 519 993 83
UK: + 44 333 300 9269
US: + 1 844 625 1570
For more information, please contact:
Anders Lundin, CFO, Q-linea AB
+46 (0)70-600 15 20
The information was submitted for publication, through the agency of the contact person set out above, at 13:30 CET on July 9, 2020.
Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.